David Figg

💊 A new survey conducted between Sept. 24 and Oct. 11, 2024, was sent to 4,135 independent pharmacy owners and received 467 responses. Among the many questions in the survey, several focused on the Medicare Drug Price Negotiations program and contracts for participating in the 2025 Medicare Part D pharmacy network. According to the survey results, most independent pharmacy owners have not finalized their 2025 Medicare Part D contracts, with only 27% of respondents saying that they have finalized their contracts and know which plans they will participate in. 📉 #MedicareNegotiations #PharmacyImpact #IndependentPharmacy #DrugPriceReform #HealthcareChanges #PharmacyLife #SmallBusinessPharmacies #PharmacyOwner #Medicare2024 #DrugCostSavings #PharmaceuticalNews #HealthcareInnovation

Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis (rerun): This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2024. --- The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: * About 33,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program.  * Five multi-billion-dollar, for-profit, publicly traded pharmacy chains and pharmacy benefit managers (PBMs)—Cigna (via Express Scripts), CVS Health, UnitedHealth Group (via OptumRx), and Walgreens, Walmart—continue to dominate the 340B contract pharmacy market. * Federal grantees are aligned primarily with the vertically intergated organizations' retail pharmacies, while hospitals rely on mail and specialty pharmacies. Over the past four years, manufacturers’ restrictions on 340B contract pharmacies have led hospitals to deepen their relationships with the largest PBMs—even as those PBMs have simultaneously limited hospitals’ direct participation in specialty pharmacy networks. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J. Fein, Ph.D., on June 21 for his latest live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only. #pbm #lifesciences #financial

The National Committee for Quality Assurance has released its annual ratings, evaluating over 1,000 health plans. Key findings: - Top performers: Only five plans earned the highest rating of five stars. - Focus on equity: NCQA has updated its methodology to prioritize health equity. - Data-driven assessment: Ratings are based on a comprehensive set of measures. Learn more: https://hubs.ly/Q02QPfT50